Stay updated on Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.

Latest updates to the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page
- Check5 days agoChange DetectedRevision tag updated from v3.5.4 to v3.5.5, indicating a small backend update to the page's version history.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe page now shows a Revision: v3.5.4, replacing the previous Revision: v3.5.3. This reflects a minor system update rather than any change to the study content or user-facing information.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision updated from v3.5.2 to v3.5.3, representing a small platform update to the page. This change does not modify study content, eligibility, or results.SummaryDifference0.0%

- Check55 days agoChange DetectedPage revision updated to v3.5.2.SummaryDifference0.0%

- Check70 days agoChange DetectedAdded 'Multiple myeloma' as a related topic and a link to the Genetic and Rare Diseases Information Center in the page's Resources section.SummaryDifference0.1%

- Check84 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.